Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Karo Bio, Merck & Co. Plan To Proceed With Phase II Clinical Evaluation Of MK-6913
Karo Bio has announced that Merck & Co. plans to enter a clinical phase IIa trial with the investigational drug candidate, MK-6913, identified as part of their joint
Karo Bio has announced that Merck & Co. plans to enter a clinical phase IIa trial with the investigational drug candidate, MK-6913, identified as part of their joint
Genfit has reported positive results in Phase II trial with its most advanced drug candidate, GFT505, in prediabetic patients with atherogenic dyslipidemia and abdominal obesity (study GFT505-2083). The
China Sky One Medical has recently passed the Chinese National Institute for the Control of Pharmaceutical and Biological Products (ICPBP) examination for two of its new products –
Ranbaxy Laboratories (Ranbaxy) has obtained FDA approval in the US to market its over-the-counter drug, Acetaminophen tablets. The company said that the tablets will be available in 650mg,
Advitech has reported that the TSX Venture Exchange (the TSX-V) has approved the previously announced consolidation of its issued and outstanding common shares on the basis of a
Sinovac Biotech has executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd (Sinovac Dalian). The JV will research, develop, produce and commercialise human-use
Idera Pharmaceuticals and Merck & Co., have extended its research collaboration for a fourth year. In December 2006, the companies entered into an exclusive license and research collaboration
Idera Pharmaceuticals has announced that Novartis will terminate its research collaboration agreement with the company, effective as of February 21, 2010. Sudhir Agrawal, chief executive officer and chief
Human Genome Sciences has submitted a Biologics License Application (BLA) to the FDA for Zalbin (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes
UK-based Synexus has recruited the highest number of patients to the South African study investigating a paediatric vaccine against rotavirus. The company recruited in excess of two thousand